A report from the American Society of Health-System Pharmacists found that total prescription drug spending in the US jumped to $772.5 billion last year, up 13.5% from 2022, largely due to the popularity of blockbuster weight loss drugs. Semaglutide was the top-selling drug in 2023 with total expenditures of $38.6 billion, followed by adalimumab at $35.3 billion and apixaban at $22.1 billion. Clinics and nonfederal hospitals accounted for $135.7 billion and $37.1 billion of total drug expenditures, respectively.

Full Story: HealthLeaders Media